刘险

    【摘要】 肺癌是一种高发、高死亡的恶性肿瘤，其中非小细胞肺癌(NSCLC)占80%以上。近年来，免疫检查点抑制剂(ICI)作为一种新型的免疫治疗手段，已经在晚期NSCLC的一线或二线治疗中显示出显著的临床效益，改善了患者的生存和生活质量。然而，仍有一部分患者对ICI不敏感或出现耐药，因此，寻找有效的预测生物标志物和开发个体化治疗策略是当前肺癌免疫治疗的重要方向。本文综述了肺癌的免疫生物学特征、ICI在肺癌中的临床应用、ICI效果的预测生物标志物以及个体化治疗策略的发展方向，并对肺癌免疫治疗的未来展望进行了探讨。

    【关键词】 肺癌 免疫检查点抑制剂 预测生物标志物 个体化治疗

    Clinical Status and Progress of Immunotherapy for Lung Cancer from Immune Checkpoints to Individualized Treatment Strategies/LIU Xian. //Medical Innovation of China， 2024， 21(07)： -183

    [Abstract] Lung cancer is a malignant tumor with high incidence and mortality， among which non-small cell lung cancer (NSCLC) accounts for over 80%. In recent years， immune checkpoint inhibitors (ICI) have shown significant clinical benefits as a new type of immunotherapy in the first or second line treatment of advanced NSCLC， improving the survival and quality of life of patients. However， there are still some patients who are not sensitive to ICI or develop resistance. Therefore， finding effective predictive biomarkers and developing personalized treatment strategies are important directions for current lung cancer immunotherapy. This article reviews the immunobiological characteristics of lung cancer ......